Literature DB >> 12697301

Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men.

D M Waterworth1, P J Talmud, J Luan, D M Flavell, C D Byrne, S E Humphries, N J Wareham.   

Abstract

Variation in the insulin responsive element (IRE) of the APOC3 promoter has been shown to be associated with insulin and glucose concentrations after an oral glucose tolerance test (OGTT) in young healthy men. We evaluated two variants in the IRE (-455T>C and -482C>T) in the Ely study, a prospective cohort study of middle-aged men (n=223) and women (n=279), to determine if the effect of these variants on glucose homeostasis could be explained by altered nonesterified fatty acid (NEFA) levels and if these effects are modulated by age and gender. Both variants had significant effects on the 30-min insulin incremental response in men alone (-482C>T, P=0.007; -455T>C, P=0.0155), with rare allele homozygotes having a 33.3% and 23.3% lower insulin increment as compared to common allele homozygotes, respectively. Thirty-minute NEFA concentrations were also significantly associated with genotype in men and levels were approximately 10% higher in carriers homozygous for the rare alleles as compared to subjects homozygous for the common alleles (-482C>T, P=0.04; -455T>C, P=0.006). In addition, there was a strong interaction between both variants and cigarette smoking affecting fasting triglyceride levels in both men (interaction: -455T>C, P=0.02; -482C>T, P=0.008) and women (interaction: -455T>C, P=0.007; -482C>T, P=0.013). Taken together, the data shows that men who carry the rare alleles of the IRE variants have disturbed glucose homeostasis and an unfavourable lipid phenotype. The finding of an elevated 30-min NEFA may be an important mechanistic link between triglyceride-rich lipoprotein (TRL) metabolism and glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697301     DOI: 10.1016/s0925-4439(03)00021-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

2.  Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons.

Authors:  M van Hoek; T W van Herpt; A Dehghan; A Hofman; A G Lieverse; C M van Duijn; J C M Witteman; E J G Sijbrands
Journal:  Diabetologia       Date:  2011-03-04       Impact factor: 10.122

3.  Plasma metabolomics and proteomics profiling after a postprandial challenge reveal subtle diet effects on human metabolic status.

Authors:  Linette Pellis; Marjan J van Erk; Ben van Ommen; Gertruud C M Bakker; Henk F J Hendriks; Nicole H P Cnubben; Robert Kleemann; Eugene P van Someren; Ivana Bobeldijk; Carina M Rubingh; Suzan Wopereis
Journal:  Metabolomics       Date:  2011-05-28       Impact factor: 4.290

4.  The association between apolipoprotein A1-C3-A5 gene cluster promoter polymorphisms and risk of ischemic stroke in the northern Chinese Han population.

Authors:  Yanzhe Wang; Fang Liu; Lei Li; Shumin Deng; Zhiyi He
Journal:  J Int Med Res       Date:  2017-06-21       Impact factor: 1.671

5.  Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.

Authors:  Laura J Corbin; David A Hughes; Andrew J Chetwynd; Amy E Taylor; Andrew D Southam; Andris Jankevics; Ralf J M Weber; Alix Groom; Warwick B Dunn; Nicholas J Timpson
Journal:  Metabolomics       Date:  2020-06-03       Impact factor: 4.290

Review 6.  Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks.

Authors:  Preethi Basavaraju; Rubadevi Balasubramani; Divya Sri Kathiresan; Ilakkiyapavai Devaraj; Kavipriya Babu; Vasanthakumar Alagarsamy; Vinayaga Moorthi Puthamohan
Journal:  Front Cardiovasc Med       Date:  2022-01-06

7.  Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus: findings from the Chinese multi-provincial cohort study.

Authors:  Jiangtao Li; Dong Zhao; Jing Liu; Miao Wang; Jiayi Sun; Jun Liu; Yan Li; Qiuju Deng; Yue Qi
Journal:  BMJ Open       Date:  2021-11-16       Impact factor: 2.692

8.  A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates.

Authors:  Ioanna Tachmazidou; George Dedoussis; Lorraine Southam; Aliki-Eleni Farmaki; Graham R S Ritchie; Dionysia K Xifara; Angela Matchan; Konstantinos Hatzikotoulas; Nigel W Rayner; Yuan Chen; Toni I Pollin; Jeffrey R O'Connell; Laura M Yerges-Armstrong; Chrysoula Kiagiadaki; Kalliope Panoutsopoulou; Jeremy Schwartzentruber; Loukas Moutsianas; Emmanouil Tsafantakis; Chris Tyler-Smith; Gil McVean; Yali Xue; Eleftheria Zeggini
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.